financetom
Business
financetom
/
Business
/
USA Rare Earth Stock Falls After Q3 Earnings Report: Here's Why
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
USA Rare Earth Stock Falls After Q3 Earnings Report: Here's Why
Nov 7, 2025 6:22 AM

USA Rare Earth Inc. ( USAR ) shares fell on Friday after the company released its third-quarter earnings report after Thursday's closing bell.

Here's a look at the details in the report. 

USAR stock is down. See the real-time price action here.

The Details: USA Rare Earth reported wider-than-expected quarterly losses of 25 cents per share, missing the Street estimate of 10 cents.

The company ended the quarter with $258 million cash and no significant debt.

Read Next: Michael Burry Is Super-Bearish On Palantir — With 5 Million Puts

“With the downstream capabilities of our magnet manufacturing plant in Stillwater well underway, which is now complimented by the metal making and strip casting capabilities of LCM, we are closing the loop within the rare earth magnet supply chain,” said Barbara Humpton, USAR CEO.

USAR Stock Price: According to data from Benzinga Pro, USA Rare Earth ( USAR ) stock was down 9.54% at $14.31 in early trading Friday.  

What Else: Rare earth mining peer MP Materials Corp. ( MP ) also reported Q3 results on Thursday — its Q3 adjusted loss of 10 cents per share beat analyst estimates for a loss of 18 cents per share.

However, MP Materials’ third-quarter revenue of $53.55 million fell short of estimates of $54.92 million, according to Benzinga Pro.

MP Stock Price: MP Materials ( MP ) stock moved lower following the print and was down 6.47% at $48.67 during pre-market trading at the time of publication Friday.

Read Next: 

Joby Stock Takes Off After Massive Q3 Revenue Beat: What To Know

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Planet Labs Gains On Multi-Year Deal With European Space Agency
Planet Labs Gains On Multi-Year Deal With European Space Agency
Jan 29, 2025
Planet Labs shares are trading higher premarket on Wednesday. On Tuesday, the company’s subsidiary Planet Labs Germany GmbH inked a multi-year agreement with the European Space Agency (ESA). As per the deal, Planet will become part of the Copernicus Contributing Missions, supplying commercial satellite data alongside ESA’s Sentinel satellites to support Copernicus services. Planet’s near-daily PlanetScope imagery and high-resolution SkySat...
VF Fiscal Q3 Adjusted Earnings, Net Revenue Rise
VF Fiscal Q3 Adjusted Earnings, Net Revenue Rise
Jan 29, 2025
07:18 AM EST, 01/29/2025 (MT Newswires) -- VF Corp. ( VFC ) reported fiscal Q3 adjusted earnings Wednesday of $0.62 per diluted share, up from $0.45 a year earlier. Analysts polled by FactSet expected $0.34. Net revenue for the quarter ended Dec. 28 was $2.83 billion, compared with $2.78 billion a year earlier. Analysts polled by FactSet expected $2.75 billion....
Canagold Allowed to Proceed with Environmental Assessment Application for New Polaris Project
Canagold Allowed to Proceed with Environmental Assessment Application for New Polaris Project
Jan 29, 2025
07:07 AM EST, 01/29/2025 (MT Newswires) -- Canagold Resources ( CRCUF ) on Wednesday said it has received a process order from the British Columbia Environmental Assessment Office to proceed with an environmental assessment application for the New Polaris project in British Columbia. During this phase, the company will prepare and submit its application while continuing engagement efforts with Indigenous...
Teva Pharm Q4 tops estimates on strong sales of its own drugs
Teva Pharm Q4 tops estimates on strong sales of its own drugs
Jan 29, 2025
JERUSALEM, Jan 29 (Reuters) - Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit sales gains in a trio of its branded drugs to treat migraines, Huntington's disease and schizophrenia. The world's largest generic drugmaker said on Wednesday it earned 71 cents per diluted share excluding one-time items in the October-December quarter, down...
Copyright 2023-2026 - www.financetom.com All Rights Reserved